Peripheral blood progenitor cells (PBPC) have become routine in autologous hematopoietic stem cell transplantation for selected patients with leukemia, lymphoma, myeloma and some solid tumors since the first reports in 1986. 1, 2 Correspondence: Dr H Hägglund, Dept of Transplantation Surgery, B56, Huddinge Hospital, S-141 86 Huddinge Sjukhus, Sweden Received 30 January 1998; accepted 3 March 1998 Kessinger et al 3 first reported transplantation of PBPC in the allogeneic situation, without cytokine mobilization of PBPC, in 1989. In 1992, two patients receiving allogeneic peripheral blood progenitor cell transplants (PBPCT) were reported to the European group for Blood and Marrow Transplantation (EBMT). Since then the use of PBPC has increased rapidly and almost 30% of all allogeneic hematopoietic stem cell transplants reported to EBMT 1996 were performed with PBPC. Previous reports show that allogeneic PBPC grafts contain increased numbers of mononuclear cells (MNC), T and NK cells, give rise to a faster hematological recovery and a similar incidence and severity of acute GVHD compared to BMT 4-9 using related donors. Due to the small number of patients, non-randomized trials and short follow-up it is so far not possible to evalute chronic GVHD, the graft-versus-leukemia (GVL) effect and long-term engraftment after PBPC. There is limited experience using unrelated PBPC. 10 The first PBPCT using an unrelated donor at our institution was performed 1994. 11 Here, we report a single center experience using related and unrelated PBPCT compared to BMT.
Patients and methods

Patients
Twenty-three consecutive patients receiving a first allogeneic transplant with PBPC between August 1994 and October 1997 at Huddinge Hospital were included in this study. There were seven patients with CML, nine with AML, three with ALL, two with myeloma, one lymphoma and one with aspartylglucosaminuria (AGU). The median recipient age was 40 (range 5-55) years. There were 15 males and eight females (Table 1) .
Treatment
Conditioning consisted of Cy/TBI in 21 and Bu/Cy in two patients. [12] [13] As GVHD prophylaxis, cyclosporine (CsA) combined with methotrexate was used in 22 and CsA combined with prednisolone in one patient.
14 Nine patients received less than four doses of MTX and 14 patients received four doses. Recipients of unrelated marrow received anti-thymocyte globulin (ATG) or OKT-3 for 5 days prior to transplantation. 15 Treatment was previously described in detail. 16 G-CSF 5 g/kg daily after transplantation until neutrophil recovery of у0.5 × 10 9 /l for 2 consecutive days was given to 21 patients.
Donors
Donors were 12 HLA-A-B and -DR identical siblings and 11 HLA-A-B and -DR identical unrelated donors, the median age was 34 (26-61) years. HLA typing was serological for class I and PCR-SSPP for class II. 17 There were 16 males and seven females ( Table 1 ). All donors were given G-CSF at a median dose of 10 (5-10) g/kg, subcutaneously once daily. Leukapheresis was performed for 1 or 2 consecutive days, starting on day 5 of G-CSF administration. One apheresis was used for 12 and two for 11 donors. Peripheral venous access was used in 21 donors, one donor needed a femoral catheter for the second aphereses and in one donor femoral catheters were used for two aphereses. All PBPC grafts were unmanipulated. In the control group, bone marrow was harvested as previously described. 18 
Control group
Twenty-three patients who underwent BMT between October 1994 and October 1997, using 12 HLA-A-B and -DR identical siblings and 11 HLA-A-B and -DR identical unrelated donors were used as controls. Twenty-two patients received Cy/TBI and one Bu/Cy. Immunosuppression was CsA combined with MTX in 21 patients and CsA combined with prednisolone in two patients. Less than four doses of MTX were used in eight patients and four doses in 15 patients. G-CSF 5 g/kg daily after transplantation was given to 19 patients. The group was matched for prognostic factors such as diagnosis, disease stage and age (Table 1) .
Flow cytometry
Approximately 10
5 cells per tube were stained with the following fluorescein-conjugated monoclonal antibodies; CD45 Fitc/CD14 PE (Simultest Leucogate; Becton Dickinson Immunocytometry System (BDIS) ErembodegemAalst, Belgium), IgG, Fitc/IgG2a PE (Simultest Control; BDIS), CD34 Fitc (HPCA-2; BDIS) CD34 PE (HPCA-2; BDIS), CD3 Fitc (UHCT-1; Dakopatts, Copenhagen, Denmark (Dako)) and CD56 PE (Leu-19; BDIS). After 15-min incubation at room temperature in the dark, erythrocytes were lysed using lysis buffer (1.5 m NH 4 Cl, 0.1 m KHCO 3 , 1 mm Na-EDTA) for 5 min at room temperature. After washing with phosphate-buffered saline (PBS) the cells were analyzed in a FACSort (BDIS) with a cyonics, 15 mW, air cooled argon-ion laser (class I) omitting blue light at 488 nm. Cellquest software was used for analyzing data (BDIS). Quantitation of MNC, CD34
+ , CD3 + and CD56
+ cells was performed in unseparated bone marrow or leukapheresis product.
Definitions
Neutrophil engraftment was defined as the first of 3 consecutive days with an absolute neutrophil count (ANC) Ͼ0.5 × 10 and bacteremia as the first positive blood culture related to a febrile episode during the first month after transplantation or discharge. 20 Chronic GVHD was assessed in patients alive beyond day 90. 21 
Statistical methods
Comparing cell yield, time to engraftment, transfusion requirements and hospitalization between the PBPC and BM group the Mann-Whitney U test was used. ) in the graft, number of MTX doses (Ͻ4 vs 4). Only factors significant at the 10% level from the univariate analysis were assessed in the multivariate analysis. The probabilities of bacteremia, acute and chronic GVHD, transplantation-related mortality (TRM), relapse, leukemiafree survival (LFS) and patient survival (PS) were compared using the method of Kaplan-Meier with the log rank test (Mantel-Haenszel).
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Results
Cell yield in the PBPC and BM grafts
The PBPC graft compared to the BM graft contained significantly more MNC, CD34
+ , CD3 + and CD56 + cells ( Table 2 ). The unrelated PBPC grafts showed a significantly increased cell yield of MNC (P Ͻ 0.001), CD3
+ cells (P Ͻ 0.001) and CD56
+ cells (P Ͻ 0.001) compared to BM grafts. Comparing sibling PBPC and BM grafts a similar increase of MNC (P Ͻ 0.001), CD3
+ cells (P Ͻ 0.001) and CD56 + cells (P Ͻ 0.001) was also found.
Engraftment
Neutrophils engrafted in all 46 patients in the PBPC and BM groups, respectively. In 18 and 17 patients platelets engrafted within 100 days after transplantation in the PBPC and BM groups, respectively. All five patients in the PBPC group who failed to recover platelets died before day 100. In the BM group, three patients died within 100 days after BMT without platelet engraftment, three patients had delayed platelet engraftment after BMT. Time to ANC and platelet engraftment was significantly faster in the PBPC than in the BM group (Table 2, Figure 1a and b). In the unrelated PBPCT situation a significant hastening of ANC Ͼ0.5 × 10 9 /l (P = 0.02), platelets Ͼ30 × 10 9 /l (P = 0.04) and platelets Ͼ50 × 10 9 /l (P = 0.02) compared to unrelated BMT was found. Using PBPC from sibling donors resulted in a faster engraftment of ANC Ͼ0.5 × 10 9 /l (P = 0.002), ANC Ͼ1.0 × 10 9 /l (P = 0.004) and platelets Ͼ50 × 10 9 /l (P = 0.04).
In 17 of 46 patients treated with less than four doses of MTX a 3 days faster engraftment of ANC Ͼ1.0 × 10 9 /l (P = 0.003) was seen. The median number of days after transplantation to achieve ANC Ͼ1.0 × 10 9 /l in the PBPC group receiving four doses of MTX (n = 14) was 17 days and with Ͻ4 doses of MTX (n = 9) 12 days (P Ͻ 0.001).
In the BM group, the corresponding figures were 18 (n = 15) and 17 (n = 8) days. The number of doses with MTX had no impact on platelet engraftment in the two groups. Among all patients who received у4.9 × 10 6 /kg CD34 + cells (above median) the median number of days to achieve platelets Ͼ30 × 10 9 /l were 16 days and Ͼ50 × 10 
Transfusions and hospitalization
The PBPC group required a medium of 5 units of platelets compared to the BM group who needed 10 units. The needs for erythrocytes and granulocytes were similar in the two groups. The need for platelets was similar in the unrelated situation comparing PBPCT and BMT. A trend for less platelet transfusions (P = 0.07) using PBPC compared to BM in the sibling situation was found. Median time to discharge was 20 days for the 18 evaluable patients in the PBPC group compared 23 days for the 17 evaluable BMT patients.
Logistic regression analysis
In logistic regression analysis using uni-and multivariate analysis, the most important factors to speed up engraftment were: for ANC Ͼ0.5; PBPCT (P = 0.003) and MNC у2.5 × 10 8 /kg recipient in the graft (P = 0.009) in univariate analysis. For platelets Ͼ30; PBPCT (P = 0.03) and sibling donor (P = 0.05) in multivariate analysis (Tables 3 and 4) .
Infections
The incidence of bacteremia within 1 month after transplantation was (5/23) 22% compared to (11/23) 48% (P = 0.06) and the incidence of CMV-viremia (two positive CMV-PCR tests) was (16/23) 70% vs (10/23) 48% (P = 0.14) in the PBPC vs BM group, respectively. In the PBPC group two patients developed CMV disease, one encephalitis and one pneumonitis; no CMV disease was seen in the BM group. 
Acute and chronic GVHD
The actuarial probabilities of grades II-IV acute GVHD did not differ significantly between the two groups, 23% for PBPC vs 22% for the BMT patients, 27% vs 28% in the recipients of unrelated stem cells and 18% vs 17% in the HLA-identical siblings. In patients at risk for developing chronic GVHD (survival Ͼ90 days after transplantation) the actuarial probabilities of chronic GVHD were 68% vs 61% (P = 0.52) in the PBPC and BM groups, respectively. In the PBPC group five of 10 cGVHD were de novo compared to two of 10 in the BM group (NS).
Outcome and causes of death
The median follow-up time was 549 (111-1060) days in the PBPC group and 598 (58-1108) days in the BM group. There were no statistical differences in 1 year TRM, relapse, LFS or PS between the two groups. Outcome and the causes of deaths are listed in Tables 5 and 6 .
Discussion
This retrospective study compared the result of transplantation with PBPC vs bone marrow from related and unrelated donors grafted during the same time period, 1994-1997. The cell yield from the PBPC donors were significantly increased, in line with reports from Körbling et al 23 and Dreger et al. 24 All 46 patients had engraftment of neutrophils. Absolute neutrophil count (ANC) Ͼ0.5 × 10 9 /l and platelets Ͼ30 × 10 9 /l recovered a median of 5 days earlier after PBPCT compared to BMT. In addition patients receiving PBPC required less platelet transfusions (P = 0.03). Using PBPC and post-transplant treatment with G-CSF in Table 6 Causes of death /l was 12 days in this study. The Seattle group 7 and the allo-PBPCT Spanish group 9 reported engraftment of ANC Ͼ0.5 × 10 9 /l after 15 and 14 days, in PBPC patients treated with CsA + MTX without post-transplant G-CSF in the HLA-identical sibling situation. PBPCT and post-transplant treatment with G-CSF seems to be an effective combination to speed up hematological recovery further after hematopoetic stem cell transplantation.
MTX, which is a cytotoxic drug, significantly delays engraftment compared to patients treated with CsA. 7 In the present study, patients who received less than four doses of MTX had a faster engraftment of ANC compared to those receiving full dose. This has also been observed by others. 5, 25 However, the number of MTX doses had no impact on time to platelet engraftment. This may indicate that MTX is less cytotoxic to megakaryocytes than myelocytes.
The faster recovery of neutrophils and platelets after PBPCT is probably caused by the greater amount of MNC transplanted, in this study one log more MNC in the PBPC graft.
A trend for a lower incidence of bacteremia (P = 0.06) was seen in the PBPC group, 22% vs 48% in the BM group. The tendency for a reduced incidence of bacteremia may be due to the significantly shorter neutropenic period, since delayed engraftment was the most important factor for bacteremia among 500 consecutive bone marrow recipients in our center. 20 With PBPC combined with G-CSF it is obviously possible to further speed up engraftment of neutrophils. Therefore, it may be especially important to use PBPC in unrelated transplants because bacteremia occurs in more than half of the patients. 26 The Seattle group reported that recipients of bone marrow died more frequently of bacterial and fungal infections than did recipients of PBPC. 7 This may be due to earlier neutrophil recovery, but a role for improved supportive care during the last years cannot be excluded. Although there was a more rapid engraftment and a trend for a lower incidence of bacteremia after PBPCT in this study, the number of days to discharge were similar in the two groups. This is due to the fact that the oral intake is important before discharge and is obviously not significantly affected by engraftment or type of graft.
The incidence and severity of acute GVHD were similar using PBPC from related 5, 6, 23, 27 or unrelated donors. Since the incidence of acute GVHD is increased after BMT using unrelated donors, 28 one might expect a further increased risk for GVHD using unrelated PBPC. In this study the actuarial probability of grades II-IV acute GVHD was 27% after unrelated PBPCT compared to 28% after unrelated BMT.
Regarding the actuarial probability of chronic GVHD no difference could be observed between the PBPCT group and the BMT group, 68 vs 61%, respectively. The chronic GVHD figures should be interpreted with caution due to the small number of patients and short follow-up.
There is a close correlation between acute and chronic GVHD. 29 Therefore an increased risk of chronic GVHD by PBPC compared to bone marrow may not be expected. On the other hand donor buffy-coat transfusions after BMT increased the risk of chronic GVHD. 30 Therefore it cannot be excluded that the increased lymphocyte content in PBPC may induce chronic GVHD. This was also reported from Seattle. 31 Are the risks for CMV infection increased after PBPCT? Theoretically yes, since one log more CMV containing MNC are transplanted (P Ljungman for the EBMT Infectious Diseases Working Party, personal communication). In our small series of patients 70% had CMV-viremia after PBPCT compared to 48% (NS) following BMT, respectively. Two patients developed CMV disease in the PBPCT group and none in the BMT group. A survey of the Infectious Diseases Working Party of the EBMT reported that the incidence of CMV disease after PBPCT is 6% using CMV-prophylaxis or pre-emptive therapy. 32 In 1996, 1137 allogeneic PBPCT were reported to EBMT and only 79 used unrelated donors. Therefore, it will probably take some time before a large controlled trial can be performed and experiences from single centers are therefore of importance.
In this study with a limited number of patients the incidence of TRM, relapse, and survival were similar between the two groups. However, we conclude that a significantly faster engraftment of neutrophils and platelets and a reduction of platelet transfusions were seen after PBPCT as compared to BMT.
